3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Pathologic Complete Response
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Interventions
Trastuzumab
5
Carboplatin
5
130-nm albumin-bound paclitaxel
3
toripalimab
2
pertuzumab
2
pembrolizumab
2
Tretinoin
2
Paclitaxel
2
Immunotherapy
2
Drug Therapy
2
Doxorubicin
2
Docetaxel
2
Cytarabine
2
zanidatamab
1
venetoclax
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
temsirolimus
1
talazoparib
1
tagraxofusp
1
sarilumab
1
sargramostim
1
pyrotinib
1
pexidartinib
1
pazopanib
1
patritumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pathologic Complete Response
×
lentiviral minigene vaccine of COVID-19 coronavirus
×
Clear all
NCT01686334
2024-03-12
WIDEA
University Hospital, Antwerp
Phase 2
Active not recruiting
130 enrolled